Tiny Gem Archives - Page 3 of 58

WednesdayJan 14, 2026 9:00 am

ParaZero Technologies Ltd. (NASDAQ: PRZO) Announces First Successful Demonstration of the Company’s DefendAir Platform in Europe

ParaZero has successfully demonstrated the company’s DefendAir platform for the first time on European soil, following a distribution agreement that was recently signed with a leading Western European distributor Around 40 senior military officers representing several NATO member states from Western Europe attended the event where ParaZero demonstrated the full capabilities of DefendAir The live exercise showcased the platforms rapid deployment, precision targeting, interception success rate, and ability to operate well in complex environments ParaZero Technologies (NASDAQ: PRZO), an aerospace defense company, recently completed the company’s first live DefendAir demonstration on European soil. The successful demonstration followed a recently signed…

MondayJan 12, 2026 10:00 am

Health IT Firms Call for Clearer, More Consistent AI Rules

Health IT firms in the U.S. are calling for clearer, more consistent AI rules as conflicting state regulations create mounting challenges for companies operating across multiple jurisdictions. Industry leaders say the fragmented approach to AI regulation threatens to slow innovation while producing unequal care standards for patients depending on their location. President Donald Trump's administration addressed these concerns with a December 11 executive order titled Ensuring A National Policy Framework For Artificial Intelligence. The directive seeks to establish unified nationwide standards rather than permitting individual states to continue developing their own methods for regulating the rapidly evolving technology. The order directs Attorney General Pam Bondi to establish an AI Litigation Task Force to address state laws deemed to be at odds with national policy. Commerce Secretary Howard Lutnick must review existing state AI legislation and…

FridayJan 09, 2026 9:00 am

GridAI Technologies Corp. (NASDAQ: GRDX) Is ‘One to Watch’

GridAI Technologies provides exposure to the convergence of artificial intelligence, energy infrastructure modernization, and large-scale electrification trends. The Grid AI platform is software-first and hardware-agnostic, supporting scalable deployment without requiring extensive new physical infrastructure. Rising power demands from AI data centers and electrified systems create structural demand for real-time energy-orchestration solutions. The company’s legacy biopharmaceutical assets provide additional optionality alongside its expanded activities in AI-driven energy infrastructure. Public-market access through its Nasdaq listing supports capital formation, visibility, and potential strategic partnerships as deployments scale. GridAI Technologies (NASDAQ: GRDX) is a company operating at the intersection of artificial intelligence and energy infrastructure following…

ThursdayJan 08, 2026 12:00 am

ParaZero Technologies Ltd. (NASDAQ: PRZO) Is ‘One to Watch’

ParaZero operates as a defense aerospace company specializing in multi-layered Counter-UAS solutions for modern battlefield and homeland security environments. The DefendAir platform offers three complementary interception layers (airborne, turret-based, and hand-held) providing forces with flexible, low-collateral responses to diverse hostile drone threats. Company-reported demonstrations with Israeli defense authorities have shown effective real-time interception across fast, maneuverable, and RF-denied drone scenarios. DropAir delivers validated precision-delivery capability for medical and tactical supplies, including successful collaboration with the Israeli Ministry of Defense and the IDF Medical Corps. Rising global demand for cost-effective and scalable Counter-UAS systems positions ParaZero for continued expansion across defense…

WednesdayJan 07, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’

LIXTE is advancing a first-in-class PP2A inhibitor platform designed to enhance, rather than replace, established chemotherapy and immunotherapy regimens. The company is conducting multiple active clinical trials in solid tumors with significant unmet medical need, supported by academic and industry collaborations. LIXTE’s scientific strategy is protected by a comprehensive patent portfolio, with management noting no known direct competitors targeting PP2A inhibition. Strategic actions in 2025, including the acquisition of Liora Technologies and a registered direct offering completed in December 2025, reflect an effort to broaden capabilities and strengthen operational flexibility. Expansion of the ovarian clear cell carcinoma trial in December…

WednesdayJan 07, 2026 9:00 am

Preclinical Study Suggests Combo Therapy Could Treat Glioblastoma

University of North Carolina researchers have developed a combination treatment that shows remarkable promise against glioblastoma, an aggressive brain cancer with dismal survival rates. The therapy paired a standard chemotherapy drug with a laboratory chemical called EdU to produce unprecedented results in preclinical models. Nobel Prize winner Aziz Sancar led the research and the findings were published in the journal Proceedings of the National Academy of Sciences. His team tested EdU alongside temozolomide, known as TMZ, across multiple glioblastoma models. The concept is straightforward: combining these two compounds can destroy tumors and prevent death, Sancar explained. Together, the drugs demonstrated…

WednesdayDec 31, 2025 9:00 am

New Gene Regulator Could Revive Immune System Response in Cancer Management

A gene regulator best known for its role in bone development is now emerging as a potential lever to restore immune responses in cancer patients who stop benefiting from immunotherapy. New findings from Taiwan suggest that blocking this regulator, RUNX2, may help worn-down immune cells regain their ability to fight tumors. National Taiwan University and National Taiwan University Hospital researchers identified RUNX2 as a key factor behind immune exhaustion in liver cancer. Their work points to RUNX2 as a driver of why immune checkpoint inhibitors, once effective, can lose their impact over time. Immune checkpoint inhibitors are designed to unleash…

FridayDec 26, 2025 9:00 am

Al Jazeera Unveils AI Tool to Support Their Teams

Al Jazeera is unveiling a new artificial intelligence platform aimed at supporting its teams as journalism becomes more data-heavy and faster paced. The initiative, called “The Core,” is being developed in partnership with Google Cloud and is designed to weave AI directly into the network’s daily news operations. The broadcaster says the project goes beyond a typical tech upgrade. Rather than treating AI as a background utility, Al Jazeera wants it to function as an active assistant throughout the news cycle. The system is intended to help journalists handle complex information, streamline internal processes, and free up time for reporting…

MondayDec 22, 2025 10:00 am

New Blood Test Reveals Whether Treatment is Working for Brain Cancer Patients

Researchers have revealed a new blood test that can determine whether brain cancer therapies are being effective. The diagnostic tool could guide glioblastoma physicians on whether to maintain current drug regimens, change medications, or halt interventions altogether. Adam Sonabend, a Northwestern Medicine neurosurgeon who co-directed a study published in Nature Communications, explained that using this test, treatment effectiveness becomes apparent after a single dose instead of months of waiting. This represents a major advancement for glioblastoma care. It could spare patients from continuing regimens that don't work while eliminating needless adverse reactions that diminish quality of life. Glioblastoma is typically lethal and claims most victims within 24 months. Since the tumors penetrate brain structures and make total surgical extraction incredibly difficult, only one…

WednesdayDec 17, 2025 10:00 am

Novel Biomarker Could Predict Resistance to Immunotherapy, Study Finds

Scientists at Northwestern Medicine have discovered a biological marker that predicts which cancer patients are more resistant to immunotherapy. Dubbed USP22, the marker also points to a potential treatment target for non-responders. Findings published in The Journal of Clinical Investigation have the potential to transform care for patients whose current options remain limited. Checkpoint blockade immunotherapy prevents harmful interactions between immune cells and cancer cells, keeping T-cells active so they can attack tumors. The approach has revolutionized cancer treatment over the past decade. However, despite early optimism about its potential to become a universal solution, immunotherapy only helps a small fraction of cancer patients. Earlier research showed that low levels of MHC-I proteins on tumor…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Category: Tiny Gem